Aimovig generated $257 million in sales in 2023. [1]
How is Aimovig Performing Commercially?
Aimovig's 2023 revenue of $257 million represents a slight increase from its 2022 sales, which totaled $251 million. [1]
When Does Aimovig's Patent Protection End?
The primary patent for Aimovig is set to expire in 2030. [2] This patent covers the drug's formulation. [2] However, additional patents related to its method of use are scheduled to expire later, in 2035. [2]
What About Competition and Biosimilars for Aimovig?
With patent expiry on the horizon, the potential for biosimilar competition exists. [3] Biosimilars are versions of biologic drugs that are highly similar to the original, with no clinically meaningful differences. [3] The development and approval of biosimilars could introduce more affordable treatment options for patients. [3]
Who Manufactures Aimovig?
Aimovig is manufactured by Amgen. [4]
What is Aimovig Used For?
Aimovig is a medication used for the preventive treatment of migraine in adults. [5] It targets the calcitonin gene-related peptide (CGRP) pathway, which plays a role in migraine headaches. [5]
What Clinical Data Supports Aimovig's Efficacy?
Clinical trials have demonstrated Aimovig's effectiveness in reducing monthly migraine days. [5] For example, in one study, patients treated with Aimovig experienced a significant reduction in the number of migraine days per month compared to placebo. [5]
Are There Potential Side Effects Associated with Aimovig?
Common side effects of Aimovig may include injection site reactions, upper respiratory tract infections, and back pain. [5] It is important for patients to discuss any concerns about side effects with their healthcare provider. [5]
Sources:
1. https://www.amgen.com/newsroom/press-releases/2024/02/amgen-announces-fourth-quarter-and-full-year-2023-results
2. https://www.drugpatentwatch.com/
3. https://www.fda.gov/news-events/public-health-campaigns/biosimilars
4. https://www.amgen.com/
5. https://www.aimovig.com/